Get started
INNATE PHARMAINNATE PHARMAINNATE PHARMA

INNATE PHARMA

No trades
See on Supercharts
Overview
Financials News Ideas Discussions Technicals Forecast Seasonals

IPH chart


Full chart

IPH upcoming earnings

Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—

Key stats


Market capitalization
‪161.43 M‬ EUR
Dividend yield (indicated)
—
Price to earnings Ratio (TTM)
—
Basic EPS (TTM)
−0.422 EUR
Net income (FY)
‪−7.57 M‬ EUR
Revenue (FY)
‪51.90 M‬ EUR
Shares float
‪56.49 M‬
Beta (1Y)
1.11

Employees


Employees (FY)
179
Change (1Y)
−31 −14.76%
Revenue / Employee (1Y)
‪289.95 K‬ EUR
Net income / Employee (1Y)
‪−42.29 K‬ EUR

About INNATE PHARMA


Sector
Health Technology
CEO
Jonathan Dickinson
Headquarters
Marseille
Website
innate-pharma.com
Founded
1999
ISIN
FR0010331421
FIGI
BBG000Q7GF31
Innate Pharma SA is a global, clinical-stage biotechnology company, which engages in developing immunotherapies for cancer patients. Its product pipeline includes Lacutamab, Monalizumab, Avdoralimab, and IPH62. The company was founded by Hervé Eloi Dominique Brailly, Eric Vivier, Marc Bonneville, Alessandro Moretta, Jean-Jacques Fournié, and François Romagné on September 23, 1999 and is headquartered in Marseille, France.

Financials


Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:—

IPH news



Ideas



See all ideas 

Technicals

Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Analyst rating


An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Seasonals


Displays a symbol's price movements over previous years to identify recurring trends.

Frequently Asked Questions


The current price of IPH is 1.938 EUR — it has increased by 1.56% in the past 24 hours. Watch INNATE PHARMA stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on EURONEXT exchange INNATE PHARMA stocks are traded under the ticker IPH.
IPH stock has fallen by −2.50% compared to the previous week, the month change is a 37.13% rise, over the last year INNATE PHARMA has showed a −24.44% decrease.
We've gathered analysts' opinions on INNATE PHARMA future price: according to them, IPH price has a max estimate of 10.89 EUR and a min estimate of 2.41 EUR. Watch IPH chart and read a more detailed INNATE PHARMA stock forecast: see what analysts think of INNATE PHARMA and suggest that you do with its stocks.
IPH reached its all-time high on Apr 27, 2015 with the price of 17.850 EUR, and its all-time low was 1.060 EUR and was reached on Oct 10, 2008. View more price dynamics on IPH chart.
See other stocks reaching their highest and lowest prices.
IPH stock is 1.98% volatile and has beta coefficient of 1.11. Track INNATE PHARMA stock price on the chart and check out the list of the most volatile stocks — is INNATE PHARMA there?
Today INNATE PHARMA has the market capitalization of ‪161.43 M‬, it has decreased by −2.83% over the last week.
Yes, you can track INNATE PHARMA financials in yearly and quarterly reports right on TradingView.
INNATE PHARMA is going to release the next earnings report on Mar 27, 2025. Keep track of upcoming events with our Earnings Calendar.
IPH earnings for the last half-year are −0.31 EUR per share, whereas the estimation was −0.28 EUR, resulting in a −10.71% surprise. The estimated earnings for the next half-year are −0.26 EUR per share. See more details about INNATE PHARMA earnings.
INNATE PHARMA revenue for the last half-year amounts to ‪12.35 M‬ EUR, despite the estimated figure of ‪12.40 M‬ EUR. In the next half-year revenue is expected to reach ‪17.32 M‬ EUR.
IPH net income for the last half-year is ‪−24.76 M‬ EUR, while the previous report showed ‪−9.29 M‬ EUR of net income which accounts for −166.62% change. Track more INNATE PHARMA financial stats to get the full picture.
No, IPH doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Dec 30, 2024, the company has 179.00 employees. See our rating of the largest employees — is INNATE PHARMA on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. INNATE PHARMA EBITDA is ‪−44.93 M‬ EUR, and current EBITDA margin is −33.36%. See more stats in INNATE PHARMA financial statements.
Like other stocks, IPH shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade INNATE PHARMA stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So INNATE PHARMA technincal analysis shows the buy rating today, and its 1 week rating is neutral. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating INNATE PHARMA stock shows the sell signal. See more of INNATE PHARMA technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.